Fenebrutinib, Genentech’s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023),…
fenebrutinib
The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the…
Recommended Posts
- MSAA expands research network aimed at improving real-world MS care
- Higher ultra-processed food intake tied to increased MS risk: Study
- Patient voices echo strong call for better MS medical care
- CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MS
- AI partnership aims to sharpen brain scans’ detection of MS